An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves
暂无分享,去创建一个
E. Copson | K. Rieger-Christ | O. Michielin | C. Dive | S. Foulon | A. Croitoru | F. Barlesi | T. Cooksley | G. Pentheroudakis | B. Besse | T. Robinson | C. Palmieri | Abin Varghese Thomas | D. Arnold | L. Turtle | Luis Castelo-Branco | C. Massard | E. Romano | A. Armstrong | A. Calles | Cong Zhou | D. Graham | A. Mosenthal | S. Ganatra | H. Frederiksen | M. Baxter | L. H. Jakobsen | M. Sekacheva | S. Dani | R. Shotton | S. Gennatas | F. Gomes | C. Hague | D. Viñal | B. Obispo | J. Rogado | N. Joharatnam-Hogan | K. Khan | L. Albiges | E. Dickens | S. Peters | A. Lewis | Rushin P. Patel | L. Horsley | A. Glenthøj | U. Khan | T. Bhogal | A. Tivey | A. Bayle | Sophie Williams | Caroline Wilson | L. Eastlake | K. Banfill | H. McKenzie | Oskar Wysocki | Dónal Landers | Andre Freitas | M. Harrison | M. Rowe | Kevin Harrington | L. Castelo-Branco | R. Lee | A. Angelakas | H. Boyce | F. Britton | P. Fitzpatrick | Richard Hoskins | P. Huddar | Z. Hudson | A. Maynard | R. Sheehan | A. Stockdale | Theingi Aung | Sam Khan | Jamie Weaver | L. Jakobsen | L. Castelo-Branco | K. Harrington | Sourbha S. Dani | Solange Peters | Sarju Ganatra
[1] M. Piccart,et al. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study , 2022, The Lancet Oncology.
[2] K. Harrington,et al. Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital , 2022, JCO clinical cancer informatics.
[3] T. Choueiri,et al. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE) , 2022, ESMO Open.
[4] S. Kalnicki,et al. Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave , 2022, Cancer Cell.
[5] T. Ndung’u,et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.
[6] M. Koopmans,et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial , 2021, The Lancet Oncology.
[7] Robert L. Goldstone,et al. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. , 2021, Nature cancer.
[8] J. Yee,et al. Clinical characteristics of the first and second COVID-19 waves in the Bronx, New York: A retrospective cohort study , 2021, The Lancet Regional Health - Americas.
[9] M. Malim,et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study , 2021, The Lancet Oncology.
[10] H. Fennema,et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.
[11] J. Warner,et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium , 2021, Annals of Oncology.
[12] Christopher M. Horvat,et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 - Preliminary report , 2021, medRxiv.
[13] A. Pettitt,et al. Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort , 2021, Leukemia & lymphoma.
[14] A. Coolen,et al. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients , 2021, Cancer Cell.
[15] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[16] C. Wilson,et al. Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome , 2020, ESMO Open.
[17] N. Chaput,et al. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort , 2020, Nature Cancer.
[18] D. Kerr,et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study , 2020, The Lancet Oncology.
[19] R. Salazar,et al. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer , 2020, Cancer discovery.
[20] K. Bhaskaran,et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.
[21] E. Robilotti,et al. Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.
[22] Alokkumar Jha,et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.
[23] D. Kerr,et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.
[24] M. Roser,et al. Coronavirus Pandemic (COVID-19) , 2020 .
[25] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[26] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .